Announced the completion of the pharmacokinetic/pharmacodynamic study of otenaproxesul’s faster-absorbing formulation for acute pain. The study was designed to confirm the drug’s safety and inform treatment regimens for the upcoming Phase II trial, on track to launch in calendar Q1 2024. Antibe Therapeutics Inc. shares T.ATE are trading unchanged at $0.69.
Stocks in play: Antibe Therapeutics Inc.
Baystreet.ca - Baystreet - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/Technology%20abstract%20by%20TU%20IS%20via%20iStock.jpg)